How can third generation anti-CD30 CARs improve treatment of CD30+ lymphomas?

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Biagio De Angelis, Ospedale Pediatrico Bambino Gesù, Rome, IT, discusses how third generation anti-CD30 CARs can improve treatment of CD30+ lymphomas.

Biagio De Angelis discusses the results of his preclinical data that examined the efficacy of his novel CAR product to eradicate tumor and its ability to establish a long term immunological memory. He also talks about how transduced T cells can be eliminated if the associated toxicities are too high.